Gaoguang Pharmaceutical (Hangzhou Gaoguang Pharmaceutical Co., Ltd.) is a China-rooted, independently R&D-driven innovative drug developer targeting major diseases and unmet clinical needs. The company is developing small-molecule therapies for autoimmune diseases and inflammation that hold global intellectual property rights and have entered Phase I and II clinical trials in China and the U.S. Its R&D team includes multiple drug development scientists with over twenty years of experience at multinational pharmaceutical companies and experts in Sino‑U.S. clinical development and regulatory filings. The team reports a track record of six innovative drugs successfully brought to market. On November 16, 2021, the company completed a ¥100 million B2 financing. Proceeds will be used for clinical research on existing programs, new indication development, new project expansion, and talent recruitment. 高光制药 is an independent, R&D-driven innovative drug company developing small-molecule therapies targeting autoimmune diseases and inflammation with global intellectual property. Its lead and follow-on programs have entered Phase I and Phase II clinical trials in China and the U.S. The company reports a strong R&D and clinical team with members who have decades of drug discovery and development experience and a track record of six innovative drugs brought to market. Management highlights include founder Liang Congxin, who has led multiple small-molecule drugs to approval, including a product with annual sales over $1 billion. 高光制药 intends to use new financing to accelerate multiple Phase II clinical programs in China and the U.S. and to advance its new pipeline product layout toward commercialization. The company emphasizes translating innovative results into breakthrough therapies to address significant unmet clinical needs.

Total raised

$44M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2021